Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...
Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the ...
Seeking Alpha on MSN5d
Emergent Biosolutions stock jumps 14% post-market on guidance raiseEmergent Biosolutions (EBS) stock rose 14% post-market after the company raised the lower end of its revenue guidance range ...
Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...
PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and PreventionGAITHERSBURG, Md., Nov. 06, 2024 ...
Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...
Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.
Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback